Blog
RSS FeedPosted by Michael Wonder on 16 Jun 2019
How to deal with the inevitable: generating real-world data and using real-world evidence for HTA purposes – from theory to action
14 June 2019 - Real-world evidence, derived from real-world data, is already used, to some extent, for health technology assessment purposes. ...
Posted by Michael Wonder on 12 Jun 2019
Behind the scenes at the PBAC
11 June 2019 - Outgoing RACGP representative Rashmi Sharma pulls back the curtain after 10 years on the Pharmaceutical Benefits Advisory ...
Posted by Michael Wonder on 03 Jun 2019
Australians’ lives have a price – a ‘quality-adjusted life year’ worth about $50,000
3 June 2019 - How much is your life worth? What would you pay to keep it? More importantly, what would ...
Posted by Michael Wonder on 02 Jun 2019
Campaign wants patients to have more influence on PBS
3 June 2019 - Australian patients should be given greater say in the medicines that receive government reimbursement as consumers ...
Posted by Michael Wonder on 14 May 2019
Analysis of sponsor hearings on PBAC decision making
14 May 2019 - Original research conducted by Melinda Flowers, Sean Lybrand and myself has been published on-line in the ...
Posted by Michael Wonder on 04 Jan 2019
Decision criteria that influence managed entry agreements
3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties. ...
Posted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 29 Oct 2018
Is 'lowest cost alternative' rapidly becoming the most common main comparator accepted by the PBAC?
29 October 2018 - Further analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting ...
Posted by Michael Wonder on 28 Oct 2018
Is the PBAC's stance on the choice of the main comparator changing?
29 October 2018 - Analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting reveals ...
Posted by Michael Wonder on 31 Aug 2018
Medicines Australia welcomes announcement LSDP Expert Panel
31 August 2018 - Medicines Australia welcomes today’s announcement by Minister for Health, the Hon Greg Hunt MP on the ...
Posted by Michael Wonder on 20 Aug 2018
Network meta-analysis in health care decision-making
20 August 2018 - Systematic reviews and meta-analyses play a crucial role in clinical decision making. ...
Posted by Michael Wonder on 08 Aug 2018
Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC—does the presence of an explicit threshold affect the ICER proposed?
8 August 2018 - The English NICE and the Australian PBAC require evidence that a new medicine represents value for money ...
Posted by Michael Wonder on 04 Jul 2018
PBAC to adopt a revised approach to considering brand equivalence/substitution for biosimilar medicines
4 July 2018 - PBAC to consult with Medicines Australia on the possible withdrawal of the TGA-PBAC parallel process for ...
Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000. ...
Posted by Michael Wonder on 13 Jan 2018
Estimating the reference incremental cost-effectiveness ratio for the Australian health system
22 December 2017 - The objective of this study was to estimate the expected incremental cost per quality-adjusted life-year (QALY) ...